Controlling persistent pain is a significant unmet need for people living with Inflammatory arthritis (IA). There is emerging evidence that patients with IA exhibit different types of pain and central sensitisation contributes significantly to chronic pain. The treatment for different pain types will differ. One way in which we might rapidly improve the treatment of pain in IA is by identifying an individual’s pain type in the clinic, then tailor their pain treatment accordingly. Currently this is not routine practice and ...

GO TO STUDY

Oesophageal squamous cell cancer (OSCC) is a cancer that grows in the food pipe and affects up to 2,000 people in the UK every year. Most patients are diagnosed when the cancer has spread to other body parts (advanced stage). As a result, the five-year survival is less than 20%. In comparison, when diagnosed early, nearly three out of four patients survive more than five years, indicating that early diagnosis improves survival. There are numerous challenges in detecting OSCC early. ...

GO TO STUDY

The purpose of this study is to evaluate the safety and human clinical response to SARS-CoV-2 challenge with the omicron variant virus, in previously SARS-CoV-2 vaccinated people. We aim to establish the optimal challenge dose that causes re-infection and identify the lowest level of infectious dose necessary to produce viral replication in the upper respiratory tract of research volunteers while minimising risk of disease progression. Investigators aim to achieve an infection model which results in no symptoms, or symptoms no ...

GO TO STUDY

This is a parallel, Phase 3 study with 2-arms for treatment that are blinded/masked for participants, the Investigator, any Investigator site staff, and the Sponsor. The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy in delaying the disability progression and the safety of up to 48 months administration of frexalimab intravenous (IV) every 4 weeks (q4w) compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time ...

GO TO STUDY

This is a multicenter Phase 2 study of TL-895 in subjects with MF or ISM. Myelofibrosis (Cohorts 1-4) Treatment for subjects with MF in Cohorts 1-4 will be open-label, with enrollment for each cohort as follows: subjects with R/R MF (Cohort 1), JAKi-intolerant MF (Cohort 2), and MF ineligible for JAKi treatment (Cohort 3 and Cohort 4). Part A will evaluate the safety and tolerability of different doses of TL-895 when administered in different schedules to determine the RP2D for each cohort. Part ...

GO TO STUDY

Psoriatic arthritis (PsA) is a chronic immune mediated inflammatory arthritis occurring in patients with psoriasis and is usually serum rheumatoid factor negative [1]. PsA affects around 20% of patients with psoriasis, is equally distributed amongst the sexes, has a tendency to be more prevalent in areas distant from the Equator and appears in most patients before age 65 [2, 3]. The disease manifestation can be heterogeneous between subjects, and the resulting musculoskeletal impairment can interfere with physical function as well ...

GO TO STUDY

This is a multi-centre, open label, FIH, multi-part trial to assess safety, tolerability, and preliminary efficacy of THEO-260 in patients with high grade serous or endometrioid ovarian cancer. The trial consists of 4 parts: Part A, Part B, Part C (optional) and Part D (optional). Part A (Dose Escalation/Finding Part): The trial part will use a model-assisted methodology for dose finding, Bayesian Optimal Interval (BOIN). Four (4) escalating dose levels are planned. In Part A, RP2D will be identified. Up to 18 ...

GO TO STUDY

Each year there are 70,000 new hip fractures in the UK, with an ongoing annual cost to health and social care services of £3 billion. After this injury, mobility and independence are so badly affected that one in six people never return home. This downward spiral of immobility and dependence contributes to a quarter of people dying within one year of the injury. National mobility targets have been set for hospitals. Firstly patients should be helped out of bed within 48 ...

GO TO STUDY

Hospital-acquired thrombosis (HAT) is defined as any VTE within 90 days of hospital admission, encompassing both deep vein thrombosis (DVT) and pulmonary embolism (PE). HAT represents a significant cause of preventable death, with over 12,000 people dying each year from hospital-associated VTE in the UK. Previous studies report that the risk of untreated high-risk surgical patients developing HAT is as high as 40-60% in orthopaedic patients and 15-40% in general surgery patients. For these patients at highest risk of VTE, key ...

GO TO STUDY

Inherited Cardiac Conditions (ICCs) are a collection of medical disorders that are associated with life-threatening heart rhythm and heart muscle adnormalities. They demonstrate a familial tendency, and a number of disease-causing gene mutations have already been identified. However, a significant proportion of affected families remain with no associated disease-causing mutation; some families have unexplained differences in the severity or type of disorder that different individuals with the same mutation demonstrate. This represents a knowledge gap that this study aims to ...

GO TO STUDY